Scalper1 News
Specialty-drug giant Actavis beat analyst Q1 estimates Wednesday, as management projected a solid future from an expanding product line aided by acquisitions. Earnings jumped 75% over the year-earlier quarter to $3.49 a share, topping analysts’ consensus by 26 cents, according to Thomson Reuters. Sales gained 40% to $2.66 billion, beating estimates by about $70 million. The stock rose 3% to 204.15 — up 93% over the past 12 months. Scalper1 News
Scalper1 News